N-(2-hydroxypropyl)methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin.: I.: New synthesis, physicochemical characterization and preliminary biological evaluation

被引:111
作者
Etrych, Tomas [1 ]
Mrkvan, Tomas [2 ]
Chytil, Petr [1 ]
Konak, Cestmir [1 ]
Rihova, Blanka [2 ]
Ulbrich, Karel [1 ]
机构
[1] Inst Macromol Chem AS CR, Prague 16206 6, Czech Republic
[2] Inst Microbiol AS CR, Prague 14220 4, Czech Republic
关键词
copolymerization; drug-delivery systems; water-soluble polymers; radical polymerization; doxorubicin;
D O I
10.1002/app.28466
中图分类号
O63 [高分子化学(高聚物)];
学科分类号
070305 ; 080501 ; 081704 ;
摘要
New method of synthesis of water-soluble polymer-drug conjugates, exhibiting remarkable anticancer activity in mice models, has been developed. In the conjugates, an anticancer drug doxorubicin (DOX) is attached to a polymer carrier based on N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer via a hydrolytically labile hydrazone bond. New methacrylamide-type comonomers, containing either hydrazide group or hydrazon of DOX, were used for copolymerization with HPMA. In contrast to the synthetic procedure described earlier the new method is simpler, cheaper, and results in a better-defined conjugate structure. The conjugates are fairly stable in buffer at pH 7.4 (model of blood stream) but release DOX under mild acid conditions modeling the tumor microenvironment. The conjugates showed significant in vivo antitumor activity in treatment of T-cell lymphoma EL-4 bearing mice with up to 100% long-term survivors. (c) 2008 Wiley Periodicals, Inc.
引用
收藏
页码:3050 / 3061
页数:12
相关论文
共 25 条
[1]  
DUNCAN R, 2003, MAKROMOL CHEM-M SYMP, V70, P157
[2]  
Etrych T, 2002, MACROMOL BIOSCI, V2, P43, DOI 10.1002/1616-5195(20020101)2:1<43::AID-MABI43>3.0.CO
[3]  
2-8
[4]   New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage:: synthesis and preliminary in vitro and in vivo biological properties [J].
Etrych, T ;
Jelínková, M ;
Ríhová, B ;
Ulbrich, K .
JOURNAL OF CONTROLLED RELEASE, 2001, 73 (01) :89-102
[5]   Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy [J].
Etrych, Tomas ;
Mrkvan, Tomas ;
Rihova, Blanka ;
Ulbrich, Karel .
JOURNAL OF CONTROLLED RELEASE, 2007, 122 (01) :31-38
[6]   Differences in the intracellular fate of free and polymer-bound doxorubicin [J].
Hovorka, O ;
St'astny, M ;
Etrych, T ;
Subr, V ;
Strohalm, J ;
Ulbrich, K ;
Ríhová, B .
JOURNAL OF CONTROLLED RELEASE, 2002, 80 (1-3) :101-117
[7]   Targeting of human and mouse T-lymphocytes by monoclonal antibody HPMA copolymer doxorubicin conjugates directed against different T-cell surface antigens [J].
Jelinkova, M ;
Strohalm, J ;
Plocova, D ;
Subr, V ;
St'astny, M ;
Ulbrich, K ;
Rihova, B .
JOURNAL OF CONTROLLED RELEASE, 1998, 52 (03) :253-270
[8]   Cytoplasmic delivery and nuclear targeting of synthetic macromolecules [J].
Jensen, KD ;
Nori, A ;
Tijerina, M ;
Kopecková, P ;
Kopecek, J .
JOURNAL OF CONTROLLED RELEASE, 2003, 87 (1-3) :89-105
[9]   Water soluble polymers in tumor targeted delivery [J].
Kopecek, J ;
Kopecková, P ;
Minko, T ;
Lu, ZR ;
Peterson, CM .
JOURNAL OF CONTROLLED RELEASE, 2001, 74 (1-3) :147-158
[10]   HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia [J].
Kovár, M ;
Mrkvan, T ;
Strohalm, J ;
Etrych, T ;
Ulbrich, K ;
Stastny, M ;
Ríhová, B .
JOURNAL OF CONTROLLED RELEASE, 2003, 92 (03) :315-330